Management transactions

Each manager must notify Optomed and the FIN-FSA of every transaction in the financial instruments of the company conducted on his/her own account.¹

Last modified: 11.3.2024

The notifications shall be made promptly and no later than three business days after the date of the transaction (T+3).

In light of Optomed’s obligation to publish such information, managers must submit an informal notice to Optomed (sakari.knuutti@optomed.com and susanna.latvala-andersson@optomed.com) on the date of the transaction and that the actual notification is made to Optomed at the latest within two business days after the date of the transaction (T+2).

The notification shall be sent in electronic format to Optomed’s insider administration (sakari.knuutti@optomed.com and susanna.latvala-andersson@optomed.com) and to the FIN-FSA (by sending a secure email at the web page https://securemail.bof.fi to the address johdonkaupat@finanssivalvonta.fi) by using the form approved by the FIN-FSA, which is available at the FIN-FSA’s website (Related Document G) and include the information specified therein. The company’s insider administration may be contacted for further information.

If a manager authorises another person (e.g. an asset manager) to make the notifications on its behalf, information thereof (and the contact details of the relevant authorised persons) shall be submitted to the insider administration in writing. Such authorisation does not relieve the relevant manager from his/her liability.

1 Under MAR, a person’s obligation to notify transactions applies in respect of the relevant person, once a total amount of EUR 5,000 has been reached within a calendar year (the threshold is calculated by adding without netting all transactions conducted within a certain calendar year).However, Optomed recommends that all transactions are notified (also below the threshold). Optomed also intends to publish all transactions notified to Optomed (whether or not the 5,000 euro limit has been reached).

 

Management holdings:

Optomed discloses manager’s transactions as stock exchange releases no later than three business days after the date of the transaction (T+3). The contents of this site are updated at least quarterly.

Board and Management shareholding 31 December 2023:

  Name

Position

 

Own and
controlled shares

Options

 

Petri Salonen

Chairman of the Board of Directors

13,680

Catherine Calarco

Member of the Board of Directors

2156

Seppo Mäkinen

Member of the Board of Directors

10,943

Reijo Tauriainen

Member of the Board of Directors

14,022

Anna Tenstam

Member of the Board of Directors

5943

Ty Lee

Member of the Board of Directors

2156

  Total

48,900

 

  Name

Position

 

Own and
controlled shares

Options

 

  Juho Himberg

CEO

  Sakari Knuutti

Chief Financial Officer

70,0001

  Markku Myllylä

Vice President, Software

180,0002

  Laura Piila

Vice President, Devices

2000

98,0003

  Total

2000

348,000

 

¹) Of which 20,000 under the 2019C option program, 6,000 under option program 2020A (expires 31 Dec 2023) and 44,000 under the 2019D option program
²) Of which 60,000 under the 2018C option program, 60,000 under the 2019A option program and 60,000 under option program 2020A (expires 31 Dec 2023).
³) Of which 18,000 under the 2015 option program, 10,000 under the 2017 option program, 20,000 options under the 2017B option program and 50,000 under the 2022A option program.